<DOC>
	<DOCNO>NCT01758523</DOCNO>
	<brief_summary>This study examine safety potential benefit medication dutasteride help men reduce stop drinking alcohol .</brief_summary>
	<brief_title>Dutasteride Treatment Reduction Heavy Drinking Men</brief_title>
	<detailed_description>Extensive preclinical study indicate neuroactive steroid medicate important effect alcohol support examination neuroactive steroid modulators treatment option alcohol use problem . Dutasteride , widely prescribe medication benign prostatic hypertrophy , block key step production neuroactive steroid represent promising candidate treatment alcohol use disorder . This study use 12-week randomized placebo control design examine safety efficacy dutasteride reduce drinking among sample 160 men hazardous level alcohol use . It additionally examine potential moderation dutasteride treatment effect common missense polymorphism neuroactive steroid biosynthetic enzyme previously report associated alcohol dependence . Identification genetic predictor medication response offer potential matching alcohol treatment medication likely respond .</detailed_description>
	<mesh_term>Alcoholism</mesh_term>
	<mesh_term>Dutasteride</mesh_term>
	<criteria>average weekly ethanol consumption least 24 standard drink ; able read English 8th grade high level ; evidence significant cognitive impairment ; willing provide sign , inform consent participate study ( include willingness stop reduce drink nonhazardous level ) ; willing nominate individual know patient 's whereabouts facilitate follow study history significant alcohol withdrawal symptom ( e.g . substantial tremor , autonomic change , perceptual distortion , seizure , delirium , hallucination ) ; current DSMIV diagnosis Alcohol Dependence clinical examination physician , deem severely alcohol dependent permit participate placebocontrolled study ( e.g . evidence serious adverse medical psychiatric effect exacerbate heavy drinking would , safety reason , lead physician urge patient totally abstinent engage empirically support treatment ) . current , clinically significant physical disease abnormality basis medical history , physical examination , routine laboratory evaluation , ( exclude patient hypertension , diabetes mellitus , asthma common medical condition , adequately control patient ongoing relationship primary care provider ) serious psychiatric illness basis history psychiatric examination ( i.e. , schizophrenia , bipolar disorder , severe psychotic major depression , organic mental disorder , current clinically significant eat disorder , substantial suicide violence risk ) ; current DSMIV diagnosis drug dependence ( nicotine dependence ) ; currently take psychotropics medication depression/anxiety disorder ( stable dose least 4 week ) , medication treatment Attention Deficit/Hyperactivity Disorder ( stable dose least 4 week ) , nonbenzodiazepine sleep medication low dose benzodiazepine equivalent 2 mg clonazepam lorazepam per day ; consider investigator unsuitable candidate receipt investigational drug</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>neuroactive steroid</keyword>
</DOC>